We're replacing BBC Sounds outside the UK and bringing you BBC.com, a seamless way to read, watch, and listen - all in one ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Amanda Bynes revealed that she plans to use the injectable drug Ozempic to help achieve her weight loss goals, noting she ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish ...